Abstract 1826P
Background
With the implementation of multidisciplinary treatment and development of multiple novel anti-cancer drugs in parallel with progress in supportive and palliative care a need for separate training and specialisation in medical oncology emerged. A Global Curriculum (GC) in Medical Oncology developed and updated by a joint ESMO/ASCO GC Task Force/Working Group (GC WG) greatly contributed to the recognition of medical oncology worldwide.
Methods
ESMO/ASCO GC WG performed a global survey on medical oncology recognition and GC adoption in 2019. The survey was developed by the ESMO/ASCO GC WG and sent to the ESMO national representative, national society or the leader of the training programme in countries with whom either ESMO or ASCO had official relations at that time.
Results
Based on our survey, medical oncology is recognised as a separate specialty or sub-specialty in 47 out of 62 (75%) countries participating in the survey; with a great majority of them (39/47, 83%) recognising medical oncology as a standalone specialty. Additionally, in 9 of 62 (15%) countries, medical oncology is trained together with haematology as a specialty in haemato-oncology or together with radiotherapy as a specialty in clinical oncology. Two-thirds of responding countries reported that ESMO/ASCO GC has been either fully or partially adopted or adapted in their curriculum. It has been adopted in a vast majority of countries with established training in medical oncology (28/41; 68%) and adapted in 12 countries with mixed training in haemato-oncology, clinical oncology or other specialty responsible for training on systemic anti-cancer treatment.
Conclusions
With 75% of participating countries reporting medical oncology as a separate specialty or sub-specialty and as high as 68% of them reporting on GC adoption, the results of our survey are reassuring. Despite a lack of data for some regions, this survey represents the most comprehensive and up-to-date information about recognition of medical oncology and GC adoption worldwide and will allow both societies to further improve the dissemination of the GC and global recognition of medical oncology, thus contributing to better cancer care worldwide.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO).
Funding
European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO).
Disclosure
T. Cufer: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Institutional, Research Grant, Local PI: MSD. M. Kosty: Financial Interests, Personal, Advisory Role: Biocept; Financial Interests, Personal, Speaker’s Bureau: Astellas Pharma; Financial Interests, Personal, Speaker’s Bureau: Genentech; Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Personal, Speaker’s Bureau: Sanofi; Financial Interests, Personal, Speaker’s Bureau: Lilly; Financial Interests, Personal, Speaker’s Bureau: Bayer; Financial Interests, Personal, Speaker’s Bureau: Medivation; Financial Interests, Personal, Speaker’s Bureau: Astellas; Financial Interests, Personal, Speaker’s Bureau: Novartis; Financial Interests, Personal, Speaker’s Bureau: Bristol-Myers Squibb; Financial Interests, Personal, Speaker’s Bureau: Janssen Oncology; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Speaker’s Bureau: Merck Sharp & Dohme; Financial Interests, Institutional, Research Grant: Genentech; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Merck Serono; Financial Interests, Personal, Other, Travel and accommodations expenses: Genentech; Financial Interests, Personal, Other, Travel and accommodations expenses: Bayer; Financial Interests, Personal, Other, Travel and accommodations expenses: Medivation; Financial Interests, Personal, Other, Travel and accommodations expenses: Astellas; Financial Interests, Personal, Other, Travel and accommodations expenses: Sanofi; Financial Interests, Personal, Other, Travel and accommodations expenses: Novartis; Financial Interests, Personal, Other, Travel and accommodations expenses: Bristol-Myers Squibb; Financial Interests, Personal, Other, Travel and accommodations expenses: Janssen Oncology; Financial Interests, Personal, Other, Travel and accommodations expenses: Pfizer; Financial Interests, Personal, Other, Travel and accommodations expenses: Merck Sharp & Dohme. P.J. Osterlund: Financial Interests, Personal, Research Grant, Grant and personal fees : Roche; Financial Interests, Personal, Research Grant, Grant and personal fees : Merck; Financial Interests, Personal, Research Grant, Grant and personal fees : Sanofi Oncology; Financial Interests, Personal, Research Grant, Grant and personal fees : Amgen; Financial Interests, Personal, Research Grant, Grant and personal fees : Bayer; Financial Interests, Personal, Research Grant, Grant and personal fees : Eli Lilly; Financial Interests, Personal, Research Grant, Grant and personal fees : Nordic Drugs; Financial Interests, Personal, Other, Personal fee: Baxalta/Shire. A. Awada: Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, Advisory Board: Eli Lilly and Company; Financial Interests, Institutional, Advisory Board: Eisai; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Institutional, Advisory Board: BMS. N. El-Saghir: Financial Interests, Personal, Other, Honoraria: Roche; Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Honoraria: MSD Oncology; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Lilly; Financial Interests, Personal, Other, Honoraria: Pfizer; Financial Interests, Institutional, Research Grant: GlaxoSmithKline; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Invited Speaker: Novartis. F. Lordick: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Beigene; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Zymeworks; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Invited Speaker: Imedex; Financial Interests, Personal, Invited Speaker: Medscape; Financial Interests, Personal, Invited Speaker: MedUpdate; Financial Interests, Personal, Invited Speaker: MerckSerono; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Promedicis; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Invited Speaker: StreamedUp!; Financial Interests, Personal, Expert Testimony: Biontech; Financial Interests, Personal, Expert Testimony: Elsevier; Financial Interests, Personal, Writing Engagements: Deutscher Ärzteverlag; Financial Interests, Personal, Writing Engagements: Iomedico; Financial Interests, Personal, Invited Speaker: Springer-Nature; Financial Interests, Institutional, Research Grant: BMS. P. Rutkowski: Financial Interests, Personal, Advisory Board: Blueprint Medicines; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Institutional, Research Grant: Pfizer. A. Tfayli: Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Invited Speaker: Pfizer. H. Wildiers: Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board: Biocartis; Financial Interests, Institutional, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Advisory Board: Eisai; Financial Interests, Institutional, Advisory Board: KCE; Financial Interests, Institutional, Advisory Board: Lilly; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: Orion corporation; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, Advisory Board: PSI Cro AG; Financial Interests, Institutional, Advisory Board: Puma Biotechnology; Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Advisory Board: Sirtex; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Personal, Other, Travel and accommodation expenses: Pfizer; Financial Interests, Personal, Other, Travel and accommodation expenses: Roche. All other authors have declared no conflicts of interest.